pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·1h ago·1 min read
save

New PDUFA agreement earmarks funds to rehire FDA reviewers after recent layoffs

Oct 8, 2026·read at Endpoints ↗RegulatoryPositive

Trade groups report that the latest PDUFA reauthorization includes a specific funding pool for the FDA.

The money is intended to replace reviewers who were let go after recent HHS staffing reductions, helping restore the agency’s review capacity.

Industry observers say the move could improve review timelines for new drug applications, though the actual impact will depend on how quickly hires are made.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “New PDUFA deal sets aside FDA money to rehire reviewers”

read at Endpoints ↗
83 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
PDUFA3

related stories

  • Aug 26Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealedBioSpace
  • Aug 24Capricor’s Duchenne therapy has new life after FDA grants 3-month extensionBioSpace
  • Aug 24FDA delays Capricor's deramiocel PDUFA date to review new dataEndpoints
  • Aug 24Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand aloneBioSpace
  • Aug 21Capricor investor calls for change as company awaits decision on Duchenne candidateBioSpace